Navigation Links
NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced positive safety data from its Phase 1 clinical study of NB-002, the company's drug candidate currently in a Phase 2 clinical trial for the topical treatment of onychomycosis.

The Phase 1 clinical study was completed in January 2007 and involved 20 subjects who received twice-daily treatments of NB-002 (0.25% or 0.5%) for 28 days. Subjects were examined on days 1, 3, 7, 14, 28 and 58 for adverse events, dermal irritation and pharmacokinetic sampling. There were no drug- related adverse events, serious adverse events or discontinuations due to adverse events in any of the subjects treated. In addition, plasma drug levels were below the limit of detection (1 ng/mL) at all time points. Based on the remarkable safety profile demonstrated in this clinical study as well as other previously conducted clinical and toxicology studies, a 42-week double-blinded Phase 2 clinical study of NB-002 was initiated by NanoBio in the first quarter of 2007.

James R. Baker, MD, NanoBio's Chairman of the Board and Chief Science Officer, commented, "A unique aspect of products derived from the company's NanoStat(TM) technology is that the treatments are not systemically absorbed and they are selectively toxic to microbes while non-irritating to the skin and mucous membranes. This Phase 1 safety data further confirms that NB-002 will offer a safe alternative to the currently available systemic products. This is a critical factor for individuals affected by onychomycosis, given approximately 95% of people with this disease remain untreated as a result of the serious toxicities associated with the oral medications on the market."

Phase 2 Clinical Study for NB-002

A randomized, double-blinded, placebo-controlled Phase 2 c
'"/>




Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:12/2/2009)... HAIFA, Isreal, December 2 /PRNewswire-FirstCall/..., a leading developer of advanced,cardiovascular s...y,s Board,of Directors approved a one-for-three fo..., payable to Cardio Vascular Medical Device shareh...e course the estimated date the stock,split will b...
(Date:12/2/2009)...VILLAGE, Nev., Dec. 2 PD...ounced that it has established the per share amoun... dividend as $1.67 per share. The dividend will be...ompany,s stock as of the December 1, 2009 record d...te per share amount of the dividend at $1.67 per s...
(Date:12/2/2009)...TON, Calif., Dec. 2 Roch...t the United States Food & Drug Administration... licensed nucleic acid test, to screen source plas...ions. The test, called the cobas® TaqScreen M...qualitative, in-vitro test for the simultaneous, d...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Hospital Group Receives 241 Million Grant to Help Patients Access Health Insurance 58697 1Hospital Group Receives 241 Million Grant to Help Patients Access Health Insurance 58697 24 000 Registered for Redlands 2nd Annual Believe and Walk for the Cure 58695 14 000 Registered for Redlands 2nd Annual Believe and Walk for the Cure 58695 24 000 Registered for Redlands 2nd Annual Believe and Walk for the Cure 58695 3Thousands of Dental Professionals Arrive in Honolulu for ADAs 150th Annual Session 58693 1Thousands of Dental Professionals Arrive in Honolulu for ADAs 150th Annual Session 58693 2
...2007 - Researchers at,the Stanford University Scho...om their new study indicating that an antidepressa...behavioral disorder,known as compulsive buying, di...ts who took it., The medication is escitalopram, a... brand name Lexapro. In the study,researchers fou...
...ng for C1-inhibitor,replacement therapy, NEW YORK,...maceuticals, Inc. (Lev) today announced positive r...-esterase inhibitor (C1-INH),for the acute treatme...udy, which is part of the company,s CHANGE trials,...ion Generation,evaluating Efficacy), the protocol-...
Other Medicine Technology:Study of Drug Therapy for Compulsive Buying Yields a Puzzle,Stanford Researcher Says 2Study of Drug Therapy for Compulsive Buying Yields a Puzzle,Stanford Researcher Says 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
(Date:12/2/2009)... , , KNOXVILLE, Tenn., Dec. 2 /PRNewswir...s presence in Southwest Florida with the acquisiti... LLC (EPN). Since January 2002, EPN has held an e...aff the emergency facilities at the Downtown Naple...ealthcare Clinic. EPN also provides the staffing f...
(Date:12/2/2009)... , Waltham, MAJoseph Balboni loves sports. An avi...n, the 46-year-old insurance agent became increasi...ue to keratoconus, a degenerative eye disorder. Un... Red Sox games, he faced the prospect of a corneal... , Then three years ago, Balboni discovered an a...
(Date:12/2/2009)... , EUROECHO 2009 is the official congress of the ...registered branch of the European Society of Cardi... imaging will be presented. , New case reports ...e latest evidence highlighting the role of this ne...t in imaging techniques, it is likely that non-inv...
(Date:12/2/2009)... , National Pen ( www.pen...retailer, announced today it is giving away 10,000... (PRWEB) December 2, 2009 -- National Pen ( www....ts retailer announced today it is giving away 10,0...ve a new way to promote business that no other com...
(Date:12/2/2009)... , Revolutionary new cell... away from users will be available in early 2010 f... (PRWEB) December 2, 2009 -- Revolutionary ...missions away from users will be available in earl...gy was recently honored with a Green Technology Aw...
Breaking Medicine News(10 mins):Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Brandeis studies evaluate visionary approach to improving eyesight 2Health News:Media alert: EUROECHO 2009 2Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2
... the leaders in our,nationwide health care debate,... to that state,s health care system in modern hist...e Christian Science church, called on,state leader...s reaching out for solutions to the problem of eff...
...dress FDA,s Next Big Challenge, Is the Food and D...Safety Information on Drugs and Devices to Physici..., FDA banned the,use of a device that repairs dama...ent injuries and death. However,on November 19, 20...
...on,International (NYSE: SCI ) announced today tha... and Eric Tanzberger, Senior Vice President and,Ch... the Merrill Lynch,Health Services Conference in N...nk of America Credit Conference in Orlando, Florid...
...all/ - The Westaim Corporation,announced today tha...of its,holdings in Canadian third party asset-back....0 million for immediate proceeds of $6.0 million....ill receive 50 per cent of any proceeds received b...
... INC., the leading,Pacific Northwest information s...on, observes its five-year anniversary tomorrow. T...commemorates the following milestones:, -- Five .... Certified by Dun & Bradstreet,s Open Rating...
...sdaq: FLEX ),today announced that it will report ..., The earnings conference call, hosted by Flextro.... PST to discuss the financial results,of the Comp...pany,s Web site at, http://www.flextronics.com . A...
Other Medicine News:Health News:Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information 2Health News:Service Corporation International to Present at Investor Conferences 2Health News:Westaim reduces ABCP exposure 2Health News:ALLDATA SHREDDING Celebrates Fifth Anniversary With 'A' Grade From Clients 2Health News:Flextronics to Report Third Quarter Results 2
Blue Line® Intubation Stylet 7.5 mm 10 mm
Blue Line® Intubation Stylet 2.5 mm 4.5 mm
Surch-Lite™ Flexible Light - 15" Sterile
Surch-Lite™ Flexible Light - 5" Non-Sterile
Medicine Products: